The frenzied race to regulatory approvals this year is coming down to the finish line. The winners can immediately pivot to the competition for the mega-blockbuster revenue gains to come as the starting gun is fired for the global race to seize market share. Pfizer $PFE and their development partners
As it waits for its acquisition by AbbVie to finalize, Cerevel reported a Phase 3 win for one of its programs in Parkinson’s disease. Patients…
Her intentions, revealed in a public filing, comes after the once-hot company’s valuation collapsed from a high of $6 billion.
Boehringer Ingelheim put the spotlight on a pipeline ripe with milestones over the next decade during its full-year 2023 earnings call with the press. Driven…
Regeneron, the 35-year-old drugmaker still led by its co-founders, is getting into the venture investing arena. The New York pharma will commit $100 million per…
Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is…
Siduma Therapeutics, a Yale spinout from Arvinas scientific founder Craig Crews, has closed, a spokesperson for the company confirmed to Endpoints News via email Thursday.…
Before Novartis went all in on MorphoSys for $2.9 billion in February, the Swiss pharma giant initially wanted just one key piece from the German…
Mark Alles has quickly put together a megaround for his latest venture, and it’s for the most sought-after pocket of oncology R&D: antibody-drug conjugates. The…
DealForma’s Chris Dokomajilar has been running the numbers again and backs up some of the things we were already pretty sure about — while raising…
Six years after the Trump administration withdrew from the Iran nuclear accord, Tehran is rapidly accumulating enriched uranium, some of it very close to weapons-grade.
